Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tamsulosin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A known ✓ | P35348 | 10/20 | 0.98 |
| ▸ | ADRA1D known ✓ | P25100 | 9/20 | 0.98 |
| ▸ | ADRA1B known ✓ | P35368 | 9/20 | 0.98 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.98 |
| ▸ | HTR1A | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.98 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.98 |
| ▸ | HTR2A | P28223 | 2/20 | 0.98 |
| ▸ | DRD3 | P35462 | 2/20 | 0.98 |
| ▸ | HTR2B | P41595 | 2/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.98 |
| ▸ | HTR7 | P34969 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tamsulosin SCHEMBL29641643 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29823016 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2319987 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL29625170 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL1560198 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL2315085 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL23428 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL9300408 | 1.00 | ADRA1A (0.98) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL356385 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 | |
| Tamsulosin SCHEMBL11815414 | 0.99 | ADRA1A (0.96) | ADRA1AADRA1DADRA1BADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8232265-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-07-31 | — | — | US | disclosed |
| EP-2247308-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | Nventa Biopharmaceuticals Corporation (US) | 2010-11-10 | — | — | EP | disclosed |
| EP-2125853-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | Nventa Biopharmaceuticals Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2009086640-A1 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2009-07-16 | — | — | WO | disclosed |
| US-20090041809-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2009-02-12 | — | — | US | disclosed |
| WO-2008106803-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | NVENTA BIOPHARMACEUTICALS CORPORATION (US) | 2008-09-12 | — | — | WO | disclosed |
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093462-A1 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | SLC5A6, PNLIP, IPMK | ADRA1A 1659/4885ADRA1D 2980/4885ADRA1B 1565/4885 |
| US-20090041809-A1 | DOUBLE-STRANDED LOCKED NUCLEIC ACID COMPOSITIONS | EIF2AK2, TLR9, ADAR | ADRA1A 4827/4885ADRA1D 4853/4885ADRA1B 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.